Morgan Stanley Denali Therapeutics Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,744,755 shares of DNLI stock, worth $43.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,744,755

Previous 1,223,878 42.56%

Holding current value

$43.1 Million

Previous $28.4 Million 78.84%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$20.96 - $31.05 $10.9 Million - $16.2 Million	520,877 Added 42.56%	1,744,755 $50.8 Million
Q2 2024 Oct 17, 2024	BUY	$14.96 - $23.22 $4.42 Million - $6.87 Million	295,752 Added 31.87%	1,223,878 $28.4 Million
Q2 2024 Aug 14, 2024	BUY	$14.96 - $23.22 $4.42 Million - $6.87 Million	295,752 Added 31.87%	1,223,878 $28.4 Million
Q1 2024 Oct 17, 2024	SELL	$15.83 - $23.35 $4.68 Million - $6.91 Million	-295,752 Reduced 24.17%	928,126 $19 Million
Q1 2024 Aug 16, 2024	SELL	$15.83 - $23.35 $781,479 - $1.15 Million	-49,367 Reduced 5.05%	928,126 $19 Million
Q1 2024 May 15, 2024	SELL	$15.83 - $23.35 $781,479 - $1.15 Million	-49,367 Reduced 5.05%	928,126 $19 Million
Q4 2023 Aug 16, 2024	SELL	$16.2 - $23.18 $3.99 Million - $5.71 Million	-246,385 Reduced 20.13%	977,493 $21 Million
Q4 2023 Feb 13, 2024	SELL	$16.2 - $23.18 $66,031 - $94,481	-4,076 Reduced 0.42%	977,493 $21 Million
Q3 2023 Nov 15, 2023	SELL	$20.63 - $30.17 $1.97 Million - $2.88 Million	-95,317 Reduced 8.85%	981,569 $20.2 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $11.9 Million - $16.7 Million	507,764 Added 89.22%	1,076,886 $31.8 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $2.99 Million - $4.46 Million	136,636 Added 31.59%	569,122 $13.1 Million
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $6.54 Million - $8.44 Million	-248,846 Reduced 36.52%	432,486 $12 Million
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $6.71 Million - $9.95 Million	258,321 Added 61.07%	681,332 $20.9 Million
Q2 2022 Oct 27, 2022	SELL	$20.88 - $35.19 $5.9 Million - $9.95 Million	-282,644 Reduced 40.05%	423,011 $12.4 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $5.9 Million - $9.95 Million	-282,644 Reduced 40.05%	423,011 $12.4 Million
Q1 2022 Oct 27, 2022	BUY	$29.0 - $47.27 $8.2 Million - $13.4 Million	282,644 Added 66.82%	705,655 $22.7 Million
Q1 2022 May 13, 2022	BUY	$29.0 - $47.27 $12.1 Million - $19.8 Million	418,397 Added 145.65%	705,655 $22.7 Million
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $4.12 Million - $5.32 Million	-96,735 Reduced 25.19%	287,258 $12.8 Million
Q3 2021 Nov 15, 2021	BUY	$48.48 - $78.23 $18.6 Million - $30 Million	383,993 New	383,993 $19.4 Million

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.31B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account